NASACORT HFA Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Nasacort Hfa, and when can generic versions of Nasacort Hfa launch?
Nasacort Hfa is a drug marketed by Sanofi Aventis Us and is included in one NDA.
The generic ingredient in NASACORT HFA is triamcinolone acetonide. There is one drug master file entry for this compound. Eighty suppliers are listed for this compound. Additional details are available on the triamcinolone acetonide profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Nasacort Hfa
A generic version of NASACORT HFA was approved as triamcinolone acetonide by SUN PHARMA CANADA on October 1st, 1986.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for NASACORT HFA?
- What are the global sales for NASACORT HFA?
- What is Average Wholesale Price for NASACORT HFA?
Summary for NASACORT HFA
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 68 |
| Clinical Trials: | 8 |
| Patent Applications: | 4,824 |
| DailyMed Link: | NASACORT HFA at DailyMed |
Recent Clinical Trials for NASACORT HFA
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Gail Gauvreau | N/A |
| Stanford University | Phase 4 |
| Sanofi | Phase 4 |
US Patents and Regulatory Information for NASACORT HFA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sanofi Aventis Us | NASACORT HFA | triamcinolone acetonide | SPRAY, METERED;NASAL | 020784-001 | Apr 7, 2004 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
